Search

RP01

It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … RP01 is a novel anti-IgE immunotherapy for allergic individuals.

Calcitonin gene-related peptide

In particular, it is a potent endogenous vasodilator. … It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue.

Omburtamab

[A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases). … [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.

Sobuzoxane

Sobuzoxane is a small molecule drug. The usage of the INN stem '-oxan(e)' in the name indicates that Sobuzoxane is a benzodioxane derivative.

G4460

N4-Hydroxycytidine

[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. … [A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation

Trafermin

Progabide

Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated

Ioglycamic acid

Simendan